RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.rxsight.com.
Details
News Market Reaction – RXST
The recorded move for RXST in the trading session of this news was +3.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
RxSight’s management is scheduled to present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.